EPD Looks Calm Before Q3 Print

Enterprise Products Partners reports Q3 2026 results on October 27 with remarkably little tension in its positioning data, making the debate about fundamentals more central than the mechanics of short selling.

Short interest is too small to drive a narrative here. At 0.8% of the free float, it has fallen 24% over the past month to roughly 17.4 million shares. The borrow market reflects that indifference: cost to borrow is just 0.40%, and availability is at 482%, meaning there are nearly five shares available to lend for every one already borrowed. That is ample room for new shorts to enter if sentiment turns, but no sign that many are trying.

Options positioning leans constructively. The put/call ratio of 0.27 is actually below its 20-day average of 0.29, running about 1.3 standard deviations light on downside protection relative to recent norms. With the ratio near the lower end of its 52-week range of 0.20 to 0.40, call activity is running ahead of puts going into the print. The stock itself added 1.5% on Friday to close at $37.08, up 0.7% on the week, modestly trailing the median 1.0% weekly gain across its closest midstream peers including ET, OKE and KMI.

The real debate is over how much the quarter's EBITDA revision matters. The bull case rests on EPD's scale, its dominant NGL franchise, strong LPG export demand with roughly 90% contracted dock capacity, and distribution coverage estimated above 1.5x with leverage in the 2.75x to 3.25x range. Management has pointed to roughly $1 billion in operational discretionary cash flow growth even after lifting capex by $300 million. Bears counter that Q3 2026 adjusted EBITDA has already been revised down to $2,689 million from $2,748 million, with full-year 2026 EBITDA now seen at $11,012 million versus $11,074 million previously. The cut reflects PDH2 downtime and margin normalization in NGL processing. Morgan Stanley, which carries an Underweight rating but raised its target to $41 in August, and JP Morgan, which trimmed its target to $42 from $43 on October 8 while staying Neutral, frame the middle ground: there is no collapse in the investment case, but at a PE of 11.6x and EV/EBITDA near 10x, execution on the organic growth backlog needs to be clean to justify a re-rating.

One ownership detail worth noting: Randa Duncan Williams, a member of the founding family, filed a Schedule 13D amendment on October 2 disclosing a stake of 32.6%, up from 32.4%, equivalent to roughly 702.6 million shares. That is a concentrated, family-aligned ownership structure that constrains the free float and sets a high bar for any activist disruption. The founding family's control stake, combined with the partnership's steady distribution history, means institutional holders are largely income-focused, and the October 27 print is more about confirming the distribution is well covered than about any dramatic reset of the investment thesis. The prior quarter's result, reported July 30, sent the stock down 1.6% on the day.

The print will test whether the revised EBITDA guidance and PDH2 recovery trajectory are enough to keep distribution coverage above 1.5x, and whether management's $1 billion cash flow growth target remains intact heading into 2027.